抑亢散联合甲巯咪唑治疗Graves病的疗效  

Efficacy of Yikang powder combined with tapazol in the patients with Graves disease

作　　者：秦树光[1] 孔繁荣[1] 梁玉江[1] 杨宝良[1] 张学东[1] 王培峰[1] 

机构地区：[1]冀中能源峰峰集团有限公司总医院核医学科,邯郸056200

出　　处：《中国新药杂志》2010年第1期39-41,55,共4页Chinese Journal of New Drugs

摘　　要：目的：探讨抑亢散联合甲巯咪唑治疗毒性弥漫性甲状腺肿（Graves痫）时，对甲状腺功能、甲状腺体积及突眼等的影响。方法：将126例Graves痫患者随机分为两组，每组63例，治疗组采用抑亢散联合甲巯咪唑治疗，抑亢散每次1袋，bid，甲巯咪唑每次10mg，tid，对照组仅服甲巯咪唑，剂量同前、治疗后15和30d随访，以后1～2个月随访1次，随访6个月以上，每次均测定游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、抗甲状腺过氧化物酸抗体（TPOAb）、抗甲状腺球蛋白抗体（TGAb）、甲状腺体积和患者的突眼度，了解并评价患者治疗后的疗效。结果：除对照组15d时症状和体征改变不明显外，两组治疗后症状及体征均有改善（P〈0．01）；改善甲亢心悸、恶热、多汗、食欲亢进、消瘦等，两组比较差异有显著性（P〈0．01）；两组TPOAb，TFGAb均逐渐下降，3和6个月时治疗组对TPOAb、TGAb、突眼及甲状腺肿大的显效率、有效率比于对照组（P〈0．05，P〈0．01）。结论：抑亢散联合甲巯咪唑治疗Graves病短期内可改善甲状腺肿症状和体征，提高甲状腺肿和甲亢性突眼的疗效，是值得推广的一种临床治疗方法：Objective：To investigate the effect of Yikang powder combined with tapazol in the patients with （;raves disease（GD）. Methods： 126 cases of GD were randomly divided into two groups. Test group was treated with Yikang powder（one pouch,bid） combined with tapazol（10mg,tid）. Control group was treated with tapazol a- lone. All subjects were evaluated with serum FT3, FT4, TPOAb, TGAb levels, goitre volume and exophthalmos at 15 and 30 d after therapy,and then every 1 - 2 month for all of the foilow-up period over 6 months. Results：The clinical symptoms and signs were significantly improved after treatment in both groups,except control group in 15 days （P 〈 0.01 ）. The efficacy on improving palpitation, aversion to heat, sweating, bulimia and maransis was better in the test group than that in the control group respeetively （P 〈 0.01 ）. TPOAb and TGAb level was decreased gradu- ally. After 6 months,tile differences of the excellence rate and effective rate between the two groups were significant in TPOAb,TGAb, goilre volnme and exophthahnos（P 〈 0. 05, P 〈 0. 01 ）. Conclusion ： Yikang powder plus tapazol can improve thyroid clinical symptoms and signs,and it showed effect on adjusting goiter volume and exophthahnos.

关 键 词：GRAVES病 抑亢散 甲巯咪唑 中西医结合 

分 类 号：R977.14[医药卫生—药品] R969.4[医药卫生—药学]